Published studies of thalidomide in myelofibrosis with myeloid metaplasia.
| Studies: . | Barosi et al (Pooled Analysis of 5 Phase II Studies)38 . | Merup et al37 . | Mesa et al39 . | Marchetti et al (unpublished data, 2003) . |
|---|---|---|---|---|
| n patients | 62 | 15 | 21 | 63 |
| Age (median, years) | 65 | 68 | 63 | 68 |
| Previous myeloproliferative disease (%) | 26 | 40 | 28 | 22 |
| Thalidomide dose, mg/day (minimum/maximum) | 100/800 | 200/800 | 50/50 | 50/400 |
| Associated drugs | Various | Various | Prednisone | Various |
| Transfusion-dependence (patients %) | 37 | 46 | 48 | 41 |
| Hemoglobin (median, g/dL) | 9.46 | 10.1 | 9.0 | 9.2 |
| Leukocytes (median, 109/L) | 7.9 | 12.6 | 7.7 | 7.5 |
| Platelets (median, 109/L) | 150 | 235 | 154 | 140 |
| Spleen size (median, cm below costal arc) | 13 | n.a. | 14 | 13 |
| Dupriez score = 2 (patients %) | 25 | 6 | 28 | 19 |
| Drop-out rate at 3 months (patients %) | 45 | 36 | 5 | 24 |
| Increase by 2 g/dL of Hb value (patients %) | 14 | 0 | 45 | 13 |
| Transfusion interruption (in transfusion-dependent patients, patients %) | 30 | 0 | 40 | 39 |
| Increase by > 50 × 109/L of platelet count (patients %) | 45 | 0 | 76 | 41 |
| —in patients with a platelet count < 150 × 109/L | 38 | 0 | 55 | 28 |
| Decrease of spleen size by > 2 cm from costal arc (patients %) | 37 | 0 | 43 | 42 |
| Any clinical response (patients %) | n.a. | 0 | 71 | 66 |
| Studies: . | Barosi et al (Pooled Analysis of 5 Phase II Studies)38 . | Merup et al37 . | Mesa et al39 . | Marchetti et al (unpublished data, 2003) . |
|---|---|---|---|---|
| n patients | 62 | 15 | 21 | 63 |
| Age (median, years) | 65 | 68 | 63 | 68 |
| Previous myeloproliferative disease (%) | 26 | 40 | 28 | 22 |
| Thalidomide dose, mg/day (minimum/maximum) | 100/800 | 200/800 | 50/50 | 50/400 |
| Associated drugs | Various | Various | Prednisone | Various |
| Transfusion-dependence (patients %) | 37 | 46 | 48 | 41 |
| Hemoglobin (median, g/dL) | 9.46 | 10.1 | 9.0 | 9.2 |
| Leukocytes (median, 109/L) | 7.9 | 12.6 | 7.7 | 7.5 |
| Platelets (median, 109/L) | 150 | 235 | 154 | 140 |
| Spleen size (median, cm below costal arc) | 13 | n.a. | 14 | 13 |
| Dupriez score = 2 (patients %) | 25 | 6 | 28 | 19 |
| Drop-out rate at 3 months (patients %) | 45 | 36 | 5 | 24 |
| Increase by 2 g/dL of Hb value (patients %) | 14 | 0 | 45 | 13 |
| Transfusion interruption (in transfusion-dependent patients, patients %) | 30 | 0 | 40 | 39 |
| Increase by > 50 × 109/L of platelet count (patients %) | 45 | 0 | 76 | 41 |
| —in patients with a platelet count < 150 × 109/L | 38 | 0 | 55 | 28 |
| Decrease of spleen size by > 2 cm from costal arc (patients %) | 37 | 0 | 43 | 42 |
| Any clinical response (patients %) | n.a. | 0 | 71 | 66 |